|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Modulation of platelet function by diabetes agents in addition to their hypoglycemic effects would contribute to cardiovascular protection Newly introduced antidiabetic drugs of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors may have anti-platelet effects, and in the case of SGLT2i and GLP-1RA may contribute to their proven cardiovascular benefit that has been shown clinically.
|
31612835 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are two classes of antidiabetic agents used in the management of diabetes based on incretin hormones.
|
31837333 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1RAs are associated with a reduction in cardiovascular morbidity and mortality in high-risk patients with diabetes.
|
31595657 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Exenatide, a synthetic version of exendin-4, is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used for treating diabetes, but its relatively short half-life is a major disadvantage.
|
31580912 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Currently, the overall risk-benefit profiles for the range of GLP-1RAs point to liraglutide and semaglutide as first-choice for the management of T2D, which has been confirmed by a recently published consensus report on the treatment of T2D from the American Diabetes Association and the European Association for the Study of Diabetes.
|
30730773 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
This study aimed to identify predictors of the efficacy of GLP-1ra on Hemoglobin A1c (HbA1c) in patients with insulin-independent diabetes.
|
30788807 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Sodium-glucose co-transporter-2 (SGLT2) inhibitors and almost all glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown, beyond their effect on glucose control, to lead to a significant decrease in the cardiovascular burden of diabetes.
|
31209982 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Glucagon-like peptide-1 is a peptide of incretin family which is used in the management of diabetes as glucagon-like peptide-1 receptor agonist (GLP-1RA).
|
31425698 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The combination of GABA and a GLP-1RA exerted additive effects on β-cell survival and function, suggesting that this combination may be superior to either drug alone in the treatment of diabetes.
|
30520247 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The p-AMPKα/NOX2/JNK1/2 pathway is essential for liraglutide to attenuate HG-induced β-cell apoptosis, which further proves that GLP-1Ras may become promising therapeutics for diabetes mellitus.
|
30772113 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate the safety of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), and its effects on body weight management in adults without diabetes.
|
31264757 |
2019 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Among them, 20 obese individuals with diabetes with inadequate glycemic control and metformin monotherapy received GLP-1Ra treatment for 3 months and were reassessed for metabolic, cognitive, olfactory, and neuroimaging changes.
|
31221697 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Network meta-analysis suggested that the progression of diabetes could be delayed to varying degrees by lifestyle and pharmacological interventions, except for angiotensin-converting enzyme inhibitors, statins, sulfonylureas and vitamin D. The risk ratios (RR) [95% credible interval (CrI)] compared with control were: GLP-1RAs 0.28 (0.15, 0.50), Orlistat 0.33 (0.18, 0.55), TZM 0.33 (0.16, 0.63), TZD 0.39 (0.27, 0.53), LST 0.54 (0.32, 0.88), lifestyle 0.58 (0.49, 0.67), LSM 0.62 (0.45, 0.80), GI 0.66 (0.46, 0.88), SU 0.67 (0.40, 1.00), Vitamin D 0.91 (0.59, 1.40), ACEI 0.93 (0.62, 1.40), statins 1.20 (0.84, 1.60).
|
31354627 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Findings on cardiovascular protection with sodium-glucose co-transporter 2 inhibitors (SGLT-2i) and some glucagon-like peptide 1 receptor agonists (GLP-1RA) support their use for older patients with diabetes.
|
30187176 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1RA and SGLT2 inhibitors, which are currently approved for use in diabetes, have shown early efficacy in NASH, and also have beneficial cardiovascular or renal effects.
|
29247356 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Findings were consistent after filtering the diabetes indication irrespective of concomitant GLM, in reports including and in those not including insulin, and for the various GLP-1RAs.
|
29449951 |
2018 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
As its glucose-lowering action is glucose dependent, a GLP-1 receptor agonist (GLP-1RA) achieves these benefits with a lower risk of hypoglycemia compared with other diabetes therapies.
|
28721686 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Results with GLP1-receptor agonists (GLP-1RA) on microvascular complications of diabetes are contrasting.
|
28748377 |
2017 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Benefits of GLP-1RAs are considered to outweigh the risks in NAFLD/NASH patients with or without diabetes.
|
28065744 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are desirable for diabetes, especially in patients with overweight/obesity.
|
29167470 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings provide an evidence base for a future clinical trial to determine whether treatment with GLP-1RAs represents potentially effective pharmacological therapy following angioplasty in patients with diabetes.
|
28969637 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for diabetes and obesity treatment, and animal studies have indicated cognitive-enhancing effects.
|
28260235 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The effect of liraglutide (GLP-1 receptor agonist) administration on glucose tolerance, insulin release, and glucose-dependent insulinotropic polypeptide level was detected in a HFD-induced diabetes C57/BL6 mouse model.
|
28290604 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent cardiovascular outcome trials demonstrate that long-term use of GLP-1RAs (liraglutide and semaglutide) reduce cardiovascular and renal complications of diabetes.
|
28942790 |
2017 |